EFFECT OF HALOGENATED BOROXINE ON HEMATOLOGICAL PARAMETERS IN RATS AND ON CREATINE KINASE ACTIVITY IN VITRO
<p style="text-align: justify;"><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">Halogenated boroxine is an important enzyme inhibitor with potential applications in cancer therapy. This study aimed to evaluate its effects on hematological parameters in rats</span><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none"> <em>in vivo</em></span><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none"><em> </em>and creatine kinase activity </span><em><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">in vitro</span></em><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">. Halogenated boroxine, administered either intraperitoneally (IP) or orally, induced route-dependent changes in hematological parameters compared with controls. IP administration significantly increased neutrophils, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC), while decreasing hematocrit (HCT). In contrast, oral administration significantly decreased lymphocytes and increased basophils, while other hematological parameters remained unchanged. These effects were more pronounced following IP administration. </span><em><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">In vitro</span></em><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">, halogenated boroxine exhibited competitive inhibition of creatine kinase without pre-incubation, whereas after a 30-minute pre-incubation, the inhibition pattern indicated a non-competitive mechanism. Further analysis showed a time-dependent shift in creatine kinase inhibition mechanism following pre-incubation, characterized by a decrease in maximum reaction velocity (V</span><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none font-size-modifier vertical-align">max</span><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">), while the Michaelis constant (K</span><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none font-size-modifier vertical-align">m</span><span class="a_GcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-none">) remained unaltered. These findings show that halogenated boroxine modulates specific hematological parameters and inhibits creatine kinase activity, with effects depending on the route of administration and experimental conditions.</span></p>